Senior Management


Catherine Isted ACMA

Chief Financial Officer

Catherine Isted was appointed to the Board in October 2021. 

Catherine joined ReNeuron from Oxford Biomedica plc, a global leading cell and gene therapy company, where she was part of the finance leadership team heading up the Corporate Development and IR, helping the business grow over 800%, enter the FTSE250 and pass through £1bn market capitalisation.

Prior to that she spent 19 years in the City at Morgan Stanley, ABN AMRO, Nomura and Peel Hunt in Healthcare equity research and equity sales roles, 12 years of which at Partner level during which time she undertook multiple IPO’s and fundraisings for companies in the Healthcare sector.

The early part of Catherine career was at Merck, Sharp and Dohme, the UK subsidiary of Merck & Co., Inc., initially as a bench scientist in their medicinal chemistry laboratories, before a career change and move into their finance team where she trained to be an accountant.

Catherine graduated with a 1st class chemistry degree and is a Chartered Management Accountant.

Randolph Corteling

Randolph Corteling

Vice President of Research

Dr Randolph Corteling re-joined ReNeuron in March 2022.

Randolph  has 24 years’ experience in medical research and drug discovery, spanning academia, biotechnology and the pharmaceutical industry. He gained his PhD in Medical and Surgical Sciences at Nottingham University, followed by three years as a Heart and Stroke Foundation Postdoctoral Fellow at the University of Calgary, Canada.

In 2007 he joined ReNeuron as a senior member of the research team where he established a deep understanding of stem cell biology and in particular the role of extracellular vesicles in cell-to-cell communication. In 2011 he was appointed Head of Cell Biology where he established the first exosome programmes at ReNeuron, which are now a major commercial opportunity for the Company. He was later promoted to Head of Research at ReNeuron.

Randolph has re-joined ReNeuron from Evox Therapeutics, a private company focused on Exosome based therapeutics for rare diseases, where he led their Disease Biology and Exosome Payloads teams.


Suzanne Hancock

Head of Operations

Suzanne Hancock was appointed Head of Operations in July 2020, having joined ReNeuron as a Programme Manager in 2017.

Suzanne has broad experience of both leadership and technical scientific roles. She joined ReNeuron from GE Healthcare, where she spent almost twelve years and held a number of managerial roles forming and leading global cross functional teams engaged in the development and delivery of new products in the Life Sciences and Cell Therapy industry. Suzanne began her career as a scientist with Amersham International where she was involved in developing cell based assays and high content image analysis platforms for drug development.

She holds a BSc in Applied Biological Sciences and in 2019 successfully completed an MSP Practitioner qualification at Cardiff University.


Prof. Stefano Pluchino

Chief Scientific Officer

Professor Stefano Pluchino was appointed Chief Scientific Officer in May 2021.

He is Reader in Regenerative Neuroimmunology and Honorary Consultant at the University of Cambridge since 2010. He obtained his MD and PhD at the University of Siena, Italy, and progressed to two consecutive post doctorate appointments at the San Raffaele Scientific Institute in Milan.

Stefano has published over 120 peer-reviewed papers and is internationally recognised as a leader and pioneer in the field of regenerative neuroimmunology. He was the recipient of the 2003 European Charcot Foundation (ECF) Award, the 2006 Sorono Foundation Multiple Sclerosis Award, the 2007 Rita Levi-Montalcini Award, the 2009 Italian Ministry of Health Young Investigator Award and the 2010 International Royan Award for outstanding research in Stem Cell Biology and Technology.

Shaun Stapleton

Shaun Stapleton

Vice President Regulatory Affairs and Pharmacovigilence

Shaun Stapleton was appointed Head of Regulatory Affairs in June 2015.

He joined ReNeuron from Voisin Consulting Life Sciences where he was a Director and Vice President of Regulatory Science. He supported clients on a number of global development and registration projects, including advanced therapies and orphan drugs.

Having graduated in Biochemistry from Imperial College, London, he began his career in research with the Imperial Cancer Research Fund, before moving into the pharmaceutical industry.

He held positions of increasing responsibility in regulatory affairs at Sterling Winthrop, Eli Lilly and Boehringer Ingelheim before becoming Senior Director of Regulatory Affairs at Ipsen, where he managed regulatory input into development programmes globally, securing new product approvals in the US, EU and internationally in the neurology, endocrinology and oncology therapeutic areas.